Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity

Law360, New York (December 20, 2016, 8:04 PM EST) -- Amphastar Pharmaceuticals Inc. urged the First Circuit on Monday to revive its suit accusing Momenta Pharmaceuticals Inc. and Sandoz Inc. of trying to block a competing generic version of a blood clot medication, accusing the drugmakers of trying to rewrite a district court decision to hold on to their antitrust immunity.

The specialty drugmaker told the First Circuit that a Massachusetts district court was wrong to conclude that the Noerr-Pennington doctrine protected Momenta from claims that it plotted with Sandoz to keep Amphastar from selling generic anticoagulant enoxaparin, known by the brand name Lovenox. The doctrine generally protects companies from antitrust...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!